Enovis (ENOV) drew fresh attention on 6 August 2026 after reaffirming its full year 2026 revenue guidance and releasing second quarter results that showed organic growth, margin improvement, and a smaller net loss.

At a share price of $26.61, Enovis has had a mixed run, with a 30 day share price return of 3.34% and a 90 day share price return of 7.38%. However, the 1 year total shareholder return declined 6.43%, suggesting some recent momentum after a weaker longer term record as investors weigh the reaffirmed guidance and improving earnings profile.

If you are looking to broaden your watchlist within medical and related technologies, this could be a useful moment to scan for healthcare focused AI opportunities using the Simply Wall St screener for 43 healthcare AI stocks

After Enovis shares edged up on the latest results yet still sit well below analyst price targets, the key issue now is whether the recent rebound already reflects the progress or if more upside could remain as the valuation is considered next.

Most Popular Narrative: 37.1% Undervalued

At $26.61, Enovis is tracking well below the most followed fair value estimate of $42.30, which is built on detailed long term forecasts and a specific discount rate of 9.64%.

The accelerating need for orthopedic care due to an aging and increasingly active global population, as well as the rising prevalence of chronic conditions like obesity and diabetes, is expanding Enovis's addressable market, creating a consistent tailwind for long-term revenue growth.

Want to see what sits behind that growth story? The narrative ties steady top line expansion, margin rebuild, and a premium earnings multiple into one valuation case.

Result: Fair Value of $42.30 (UNDERVALUED)

However, Enovis still faces real tests, including the risk that complex acquisitions prove harder to integrate and that delays in new technology rollouts weaken its competitive edge.

Next Steps

With both risks and rewards in play for Enovis, this is a good time to review the underlying data yourself and move quickly. To see the mix of potential upside and the issues investors are watching, check the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Enovis?

If you stop at Enovis, you could miss other compelling setups. Use the Simply Wall St screener to quickly spot stocks that match your style and risk comfort.

• Target potential bargains by scanning for companies that combine quality fundamentals with appealing prices using the 52 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with strong balance sheets through the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for underfollowed opportunities by checking the screener containing 21 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.